GHK-Cu (Copper Peptide) vs Teriparatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper peptide found in human plasma, saliva, and urine. It plays important roles in wound healing, tissue repair, and has shown anti-aging properties in research.
Full details →Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Side-by-Side Comparison
| Aspect | GHK-Cu (Copper Peptide) | Teriparatide |
|---|---|---|
| Dose Range | 1 mg–2 mg | 20 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 4–8 weeks | 52–104 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Attracts immune cells and fibroblasts to wound sites, stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and has antioxidant effects. Modulates gene expression related to tissue repair. | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. |
| Typical Dosage | Topical: Applied as serum or cream 1-2 times daily. Injectable: 1-2mg daily for research purposes. Microneedling protocols often use 0.5-1%. | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. |
| Administration | Most commonly used topically for skin applications. Can be injected subcutaneously for systemic effects. Often combined with microneedling for enhanced skin penetration. | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. |
| Side Effects | Topical use is generally well-tolerated. May cause temporary skin irritation or redness in sensitive individuals. Injectable use may cause injection site reactions. | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. |
| Best For |
What They Have in Common
GHK-Cu (Copper Peptide), Teriparatide are both commonly used for:
Which Has Stronger Evidence?
| Goal | GHK-Cu (Copper Peptide) | Teriparatide |
|---|---|---|
| Recovery & Healing | high | high |
Key Studies
GHK-Cu (Copper Peptide)
- Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs.
Research square, 2026
- Glycyl-L-histidyl-L-lysine-Cu2(+) (GHK-Cu) Attenuates CuSO(4) or LPS induced-inflammation in Zebrafish larvae model.
European journal of pharmacology, 2026
- The Regenerative Potential of GHK-Cu in Aesthetic Medicine.
Aesthetic surgery journal, 2026
Teriparatide
- Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.
JAMA, 2026
- The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis.
The Journal of clinical endocrinology and metabolism, 2025
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis.
Journal of bone and mineral metabolism, 2025
Ready to Learn More?
Looking for trusted sources?